Flares Not Increased Following Recombinant Zoster Vaccine Injections Save
Insurance claims analysis has shown that the use of the (CDC recommended) recombinant zoster vaccine (RZV) for prevention of herpes zoster (HZ) was highly used in patients with immune-mediated inflammatory diseases (IMIDs) and was safe, as higher rates of arthritis flares were not evident.
In 2018, CDC recommended the recombinant zoster vaccine (RZV) for HZ prevention in immunocompetent ≥50 years-olds. This study examined rates of RZV vaccination (adults ≥50 years) among IMIDs patients during 2018–2019 and sought to identify presumed flares (defined as hospitalization/emergency department visits, or steroid treatment).
Among IMID patients, between 15% (commercial) and 43% (Medicare) received ≥1-dose of RZV (77 - 85% completed 2 doses). Flares were seen in 10% and 13% prior to RZV vaccination and in 9% and 11–12% after RZV vaccination. Thus no significant increase in flares following RZV administration was observed in IMID patients following RZV dose-1 or dose-2.